Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More Details
Flawless balance sheet, good value and pays a dividend.
Share Price & News
How has Boiron's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BON has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BON exceeded the German Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: BON exceeded the German Market which returned 6.2% over the past year.
Price Volatility Vs. Market
How volatile is Boiron's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Boiron undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BON (€40.4) is trading above our estimate of fair value (€29.76)
Significantly Below Fair Value: BON is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BON is good value based on its PE Ratio (17.5x) compared to the XE Pharmaceuticals industry average (21.5x).
PE vs Market: BON is good value based on its PE Ratio (17.5x) compared to the German market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: BON is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: BON is good value based on its PB Ratio (1.5x) compared to the DE Pharmaceuticals industry average (3.3x).
How is Boiron forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BON's forecast earnings growth (30.2% per year) is above the savings rate (0.2%).
Earnings vs Market: BON's earnings (30.2% per year) are forecast to grow faster than the German market (27.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BON's revenue is expected to decline over the next 3 years (-0.7% per year).
High Growth Revenue: BON's revenue is forecast to decline over the next 3 years (-0.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BON's Return on Equity is forecast to be low in 3 years time (8.5%).
How has Boiron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BON has a large one-off loss of €63.5M impacting its June 30 2020 financial results.
Growing Profit Margin: BON's current net profit margins (7.2%) are higher than last year (6.1%).
Past Earnings Growth Analysis
Earnings Trend: BON's earnings have declined by 15.5% per year over the past 5 years.
Accelerating Growth: BON's earnings growth over the past year (12.8%) exceeds its 5-year average (-15.5% per year).
Earnings vs Industry: BON earnings growth over the past year (12.8%) underperformed the Pharmaceuticals industry 12.8%.
Return on Equity
High ROE: BON's Return on Equity (8.3%) is considered low.
How is Boiron's financial position?
Financial Position Analysis
Short Term Liabilities: BON's short term assets (€415.2M) exceed its short term liabilities (€183.2M).
Long Term Liabilities: BON's short term assets (€415.2M) exceed its long term liabilities (€92.5M).
Debt to Equity History and Analysis
Debt Level: BON's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: BON's debt to equity ratio has reduced from 2.4% to 1% over the past 5 years.
Debt Coverage: BON's debt is well covered by operating cash flow (1750.1%).
Interest Coverage: BON earns more interest than it pays, so coverage of interest payments is not a concern.
What is Boiron current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BON's dividend (2.63%) is higher than the bottom 25% of dividend payers in the German market (1.17%).
High Dividend: BON's dividend (2.63%) is low compared to the top 25% of dividend payers in the German market (3.61%).
Stability and Growth of Payments
Stable Dividend: BON's dividend payments have been volatile in the past 10 years.
Growing Dividend: BON's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.9%), BON's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BON's dividends in 3 years are forecast to be well covered by earnings (42.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Valérie Lorentz-Poinsot (51 yo)
Ms. Valerie Lorentz-Poinsot serves as General Manager and Director of Development of Boiron SA and served as its Deputy General Manager since July 01, 2011. Ms. Lorentz-Poinsot has been an Executive Direct ...
CEO Compensation Analysis
Compensation vs Market: Valérie's total compensation ($USD994.44K) is about average for companies of similar size in the German market ($USD1.31M).
Compensation vs Earnings: Valérie's compensation has been consistent with company performance over the past year.
|GM & Executive Director||1.67yrs||€841.10k||0.010% |
|Deputy GM||4.67yrs||€1.18m||no data|
|Administrative & Financial Director||0.67yr||no data||no data|
|Group Marketing Director||0.67yr||no data||no data|
|Sales Director||0.67yr||no data||no data|
|Deputy General Manager||no data||no data||no data|
|Group Treasurer||18.83yrs||no data||no data|
Experienced Management: BON's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|GM & Executive Director||1.67yrs||€841.10k||0.010% |
|Independent Director||10.33yrs||€45.63k||no data|
|Chairman of the Board of Directors||9.17yrs||€296.09k||3.4% |
|Employee Shareholder Representative Director||3.33yrs||€57.98k||no data|
|Employee Representative Director||2.25yrs||€92.44k||no data|
Experienced Board: BON's board of directors are seasoned and experienced ( 10.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boiron SA's company bio, employee growth, exchange listings and data sources
- Name: Boiron SA
- Ticker: BON
- Exchange: DB
- Founded: 1932
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €699.463m
- Shares outstanding: 17.51m
- Website: https://www.boiron.com
Number of Employees
- Boiron SA
- 2, avenue de l’Ouest Lyonnais
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BOIR.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1992|
|BOI||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Jan 1992|
|BON||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1992|
|0DTF||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jan 1992|
|BOIP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jan 1992|
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded home ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/19 03:03|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.